Forbes has featured Cube Labs in its “Small Giants” Editorial, which focuses on small and medium-sized enterprises in the Italian landscape with giant projects, goals, and objectives.<\/p>\n\n\n\n
Cube Labs has been included in the list of Small Giants for its unique business model in Italian healthcare technology space, which allows the company to enable innovation in the Life Science sector, with twenty employees, three international branches, ten strategic partnerships, twelve established start-ups, twenty international patents, five exclusive licenses and thirty technologies.<\/p>\n\n\n\n
The strength of Cube Labs\u2019 business model is showcased through the example of the COVID-19 prophylactic technology that has been developed in partnership by two of Cube Labs\u2019 portfolio companies, Adamas Biotech<\/a> and DTech<\/a>. <\/p>\n\n\n\n Operating as a venture builder, Cube Labs actively selects, optimizes and amplifies internal project synergies over time to catalyze innovation.<\/p>\n\n\n\n Read the full article (English version): https:\/\/cube-labs.com\/wp-content\/uploads\/2021\/09\/allegato-100-IMPRESE-DA-CAMPIONI-copia.pdf<\/a><\/p>\n\n\n\n Read the full article (Italian Version): https:\/\/cube-labs.com\/wp-content\/uploads\/2021\/09\/Forbes_Small-Giants.pdf<\/a><\/p>\n\n\n\n